Indian pharma market is flooded with various fixed drug combinations. Among them, one of the widely used FDC is montelukast + levocetirizine. This is prescribed for the patients of any age group (paediatrics, adults and geriatric) and used as a long term therapy for the treatment of conditions such as prophylaxis, acute and chronic types of asthma, relief of symptoms of seasonal and perennial allergic rhinitis, prevention of exercise induced bronchoconstriction and chronic idiopathic urticaria. It is very essential to check the rational use of this FDC. Generally fixed dose combinations create confusions among physicians, because it contains more than one drug in various doses and it is very difficult to remember all these details and another issue with the FDCs are that the entire FDC cannot be used if the patient is contraindicated to any of the drug in the FDC. And patient specific dose calculation is also difficult with FDCs. There are very less clinical trial data available about the safety and efficacy of this agent. Objective of this review article is to check the rational use of montelukast levocetirizine FDC. To achieve the objective, all the literatures related to montelukast levocetirizine FDC were collected and analysed. The study concluded that some differences are there in the pharmacokinetic parameters of both these agents includes duration of action. In dosing also, levocetirizine dose can vary from 2.5m g to 10mg once daily whereas montelukast dosing is 10mg. Rationality of this FDC can be further supported by more clinical trial data to conform the rationality of these FDC.
INTRODUCTION
Rational drug use defined by WHO "Patients receive medications appropriate to their clinical needs, in doses that meet their own individual requirements, for an adequate period of time and the lowest cost to them and to their community" 1 . Fixed dose combination can be defined as a single dosage form which includes two or three active pharmaceutical ingredients, manufactured and distributed in fixed doses. FDCs of drugs are important for public health perspective and commonly used for treatments of pain and inflammation, hypertension, diabetes mellitus, tuberculosis, malaria, HIV etc 2 . Thousands of FDCs are available in India 3 . FDCs have advantages like they offer a simple dosage schedule which improves patient complaints and therefore improves treatment outcome. However FDCs have certain disadvantages like FDCs can confuse physician because it contain multiple ingredients and doses. Since fixed dose combination contain more than one drug and it may cause therapeutic confusion that every patient may not need all the drugs in an FDC and in case if any of these drugs in the FDC is contraindicated to a patient causes the entire FDC unfit for the therapy. Every patient is unique and characteristic such as weight, age, co-morbidities will demand individualised dose calculation which is not possible for FDCs. The rationality of FDCs should be based on certain aspects such as the drugs in the combination should act by different mechanisms, the pharmacokinetics must not be widely different and the combination should not have supra-additive toxicity of the ingredients. And most FDCs have the demerits like dosage alteration of one drug is not possible without alteration of the other drug.
Differing pharmacokinetics of constituent drugs pose the problem of frequency of administration of the formulation and by simple logic there are increased chances of adverse drug effects and drug interactions compared with both drugs given individually 4 .
Approval of FDCs in India
FDC in India is treated as new drug as per the rule 122E of drugs and cosmetic rule. This is because of the fact that by combining two or more drugs the safety efficacy and bioavailability of the individual API may change. DCGI (Drug controller general of India) is the licensing authority notified under section21 (b) of drugs and cosmetic act. The rationality of FDC is examined in the office of DCGI as per the provision of schedule Y before its market authorisation in the country. The applicant pharmaceutical company should submit exhaustive information justifying the rational of the FDC is in question. The examination process also involves external experts in their relevant field including pharmacologist. The safety and efficacy is later ascertained by conducting clinical trial and bioequivalence studies. Once the data from clinical study has been found satisfactory by the DCGI, permission to manufacture and market the FDC is granted 4, 5, 6, and 7 . Indian pharma market is flooded with various irrational FDCs; recently the Health Ministry banned 344 FDCs through a gazette notification. These include several common cough syrup solutions, analgesics and antibiotic combination, many of which are sold over the counter. The reason for banning FDC is the irrational use of drugs in the market 8 .There are millions of unapproved, unsafe, dangerous and even lethal drugs being sold in the Indian market. It is mandatory for FDCs to get an approval from the CDSCO (Central drugs standard control organisation) since 1961; however, there are still a large proportion of unapproved FDC drugs often sold over the counter in the country. One such example is selling a combination of the antibiotics cefixime and azithromycin without an approval from the central government. This combination is not approved for sale in major pharmaceutical market including US, UK, Germany, France and Japan. After the ban, the company was forced to immediately stop the manufacture and sale of its powerful antimicrobial agent. In 2007, the CDSCO banned from sale of about 294 FDCs because they had never been approved by the central regulation but had been granted manufacturing/ distributing licenses by state drug authorities, and the list was published in 2014. 9, 10 Unofficially it has been found that about 1000's of drugs are under constant vigilation and they are at an increased risk of being banned. For thetime being they are given a warning which may be taken back if the rationality of these drugs is not improved. About 344 FDC's were banned in India by the health ministry in the year 2016 including fixed dose combination of Levocetirizine+ Montelukast+ Acebrophyline. Montelukast and levocetirizineis one of the widely used FDC in India, which is used as a long term therapy in all age population (Infants, children, adults and geriatrics) for the treatment of conditions such as prophylaxis, acute and chronic types of asthma, relief of symptoms of seasonal and perennial allergic rhinitis, prevention of exercise induced bronchoconstriction and chronic idiopathic urticaria. However the studies about the rationality behind the FDC is not available in India and hence an assessment is required as it will help clinician to get an evidence based analysis about this FDC and thereby improves the patient compliance. Hence the awareness of society towards this FDC can be improved. The use of Montelukast in the case of reversal of bronchospasm in acute asthma attacks is not approved by the FDA.
METHODS
This was an evidence review conducted with an aim to check the rationality of Montelukast + levocetirizine FDC. The study period was 3 months. Materials and methods used in the study were as follows:
Identifying the scope of the work
Montelukast levocetirizine FDC is one of the widely prescribed fixed drug combinations in India.
It is widely prescribed for paediatric patients also. Hence, it was very important to check the available evidence to confirm the rationality of the same.
Collection of data
All the open access articles about montelukast and levocetirizine in Medline & Pub-med were collected. Drug Information Software Lexicomp was used to study the PK/PD of both the drug. Detailed pharmacokinetic and pharmacodynamic data were collected separately for both levocetirizine and montelukast from Lexicomp.
Analysing the data
Pharmacokinetic and pharmacodynamic parameters of both these drugs were compared using the data from software Lexicomp to check whether it is justified to give both these agents as an FDC. All the available literature were analysed to check whether the rationality of this FDC was proven in any of the clinical trial conducted in India.
DISCUSSION

Pharmacology of montelukast and levocetirizine
The pharmacokinetic and pharmacodynamic properties of Monteleukast and levocetirizine are compared in the following Table- 1. 11 This randomized study was done at the outpatient department of Gian Sagar Medical College and Hospital, District Patiala in people aged between 18-60 years old of both sexes with a clinical history of perennial allergic rhinitis for at least 1 year, to compare the effectiveness of montelukast combined with levocetirizine once daily to levocetirizine alone for a 6-week treatment course of allergic rhinitis. They randomised patients as control group (Levocetirizine) and treatment group (Montelukast+ Levocetirizine). Duration of study was 6 weeks. Study concluded that the total daytime nasal symptom, composite symptom and night time nasal symptom scores showed a significant change in treatment group than in the control group. Patients in both groups reported with nausea, dizziness, fatigue, headache, somnolence, restlessness, dry mouth, fever and weakness but none of the adverse event reported was severe that required termination of treatment. Prateek Nayak et al., (2013) 12 A randomized, open label, prospective, comparative, multi centric study was conducted to compare the efficacy and safety of Montelukast and fexofenadine fixed dose combination vs Montelukast and Levocetirizine fixed dose combination in allergic rhinitis. This study was conducted at 4 sites (Mumbai, Chennai, two cites of Bangalore) in 100 subjects divided as two group, 62 in Montelukast+Levocetirizine group and 56 in Montelukast+Fexofenadine group by administering the drugs once daily for 14 days. This study concluded that montelukast+fexofenadine showed better improvement in symptoms of allergic rhinitis compared to Montelukast + Levocetirizine. Samidh shah et al., (2015) 13 analysed the rationality of antimicrobial and respiratory fixed dose combinations available in Indian market. Antimicrobial and respiratory FDCs enlisted in Indian drug review in 2010 and 2013 were analysed. Each FDC was assessed forthe number of active pharmacological ingredients, approved by regulatory authority, listing in world health organisation (WHO) essential medicine list (EML) or national list of essential medicine and there efficacy, safety, pharmacokinetic and pharmacodynamic interactions and advantages of each FDC were also analysed by evidence based literature search. Each criterion was scored one for positive, minus one for negative or unfavourable observation. The total score for the tool was 12 and the score greater than or equal to 7 was considered rational. The study concluded that FDCs of Montelukast with antihistaminic was found to be rational due to its enhanced and complimentary pharmacological and clinical effects leading to a reduction in the day and night time symptoms effectively in patients of allergic rhinitis. Even though FDCs score for Montelukast + Levocetirizine was ≥ 7 it was not enlisted in WHO EML, 2013. Angelika batta et al., (2015) 14 a retrospective observational study carried out at the outpatient medicine department of mahathma Gandhi medical hospital, jaipur by collecting 500 prescriptions for 6 months duration showed that often prescribed medications were FDC for asthma patients. The study reports that out of 60 FDCs prescribed only three were enlisted in the Esssential Medicine List of WHO. Levocetirizine, an anti histaminic has no role in asthma as the main mediators are Leukotriene and platelet activating factor. In mild and persistent asthma cases Montelukast is recommended only if inhaled steroids cannot be prescribed for some suitable 
CONCLUSION
Montelukast +Levocetirizine FDC is widely prescribed in India and is not approved/available in the US & various countries in the European continent. The pharmacological and pharmacokinetic parameters of these agents do not match to make a combination with fixed doses as the duration of action is greater than 24 hours in case of Montelukast and is 24 hours only, in case of Levocetirizine. Normal Dosing of Montelukast is 10mg once daily, whereas in Levocetirizine the dose varies from 2.5mg to 5mg once daily. Hence when these are made into a fixed dose combination the appropriate dose required for a patient may not be achieved. Neither there are studies, which justify these differences in pharmacokinetic parameters between these agents. Majority of the available clinical trial data are about the combination therapy of both these agents, where Levocetirizine is used in different doses as per the patient needs and no trial data was available across various countries/continents for the fixed drug combination. Rationality of Levocetirizine + Montelukast FDC cannot be explained with the available insufficient data and so we conclude that this combination is irrational, till there are some randomised controlled trials to prove this otherwise.
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